Sterling Capital Management’s Monte Rosa Therapeutics GLUE Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$29.2K Buy
2,450
+2,190
+842% +$37.5K ﹤0.01% 2005
2026
Q2
$6.29K Sell
260
-1,745
-87% -$33K ﹤0.01% 2491
2026
Q1
$33K Sell
2,005
-7,503
-79% -$143K ﹤0.01% 1808
2025
Q4
$149K Buy
9,508
+6,290
+195% +$84.8K ﹤0.01% 1390
2025
Q3
$23.8K Buy
3,218
+2,051
+176% +$10.9K ﹤0.01% 2063
2025
Q2
$5.26K Buy
1,167
+454
+64% +$2.02K ﹤0.01% 2480
2025
Q1
$3.31K Sell
713
-611
-46% -$3.75K ﹤0.01% 2367
2024
Q4
$9.19K Buy
1,324
+1,177
+801% +$8.83K ﹤0.01% 2199
2024
Q3
$779 Buy
+147
New +$742 ﹤0.01% 2669

Other funds holding GLUE

Sterling Capital Management's GLUE Position: Q3 2026 in Review

Sterling Capital Management increased its Monte Rosa Therapeutics (GLUE) stake by 842% in Q3 2026, buying an estimated $37.5K and bringing the position to 2,450 shares worth $29.2K. The position accounts for ﹤0.01% of the portfolio, ranked #2005.

Sterling Capital Management first reported a position in GLUE in Q3 2024 and has held it in 9 quarters since. The position peaked at $149K in Q4 2025. 190 funds tracked by Wall St. Rank hold GLUE as of Q3 2026.

  • Sterling Capital Management held 2,450 shares of Monte Rosa Therapeutics worth $29.2K as of Q3 2026.
  • Sterling Capital Management bought 2,190 Monte Rosa Therapeutics shares in Q3 2026, an estimated $37.5K.
  • Monte Rosa Therapeutics made up ﹤0.01% of Sterling Capital Management's portfolio in Q3 2026, its #2005 holding.
  • Sterling Capital Management first reported a position in Monte Rosa Therapeutics in Q3 2024 and has held it in 9 quarters since.
  • Sterling Capital Management's Monte Rosa Therapeutics position peaked at $149K in Q4 2025.
  • 190 funds tracked by Wall St. Rank held Monte Rosa Therapeutics as of Q3 2026.

Based on Sterling Capital Management's 13F filing for Q3 2026, filed 22 Oct 2026.